Xenotransplantation

01Overview and value chain

Markers: [EC: GMO Directive 2001/18/EC & ATMP Regulation | OECD: bio-pharma | Regulator: FDA (US), EMA (EU), NMPA (CN)]

Xenotransplantation transplants living organs, tissue or cells from one species into another — specifically, from multiplex gene-edited pigs into humans — to address a chronic shortage of human donor organs that leaves dozens of patients dying on transplant waitlists every day. CRISPR-Cas9 multiplex genome editing has moved the field from research concept to clinical reality: eGenesis received FDA IND clearance for its lead candidate EGEN-2784, a genetically engineered porcine kidney, to begin a formal clinical trial for end-stage kidney disease, building on an ongoing expanded-access compassionate-use program. United Therapeutics’ 10-gene-edited UHeart received FDA clearance to proceed with the EXPRESS clinical trial, a Phase 1/2/3 adaptive (“phaseless”) design for pig-heart xenotransplantation. In China, Chengdu-based Zhongke Aoge Biotech has kept a gene-edited pig kidney functioning in a non-human primate recipient for more than 600 days in collaboration with Huazhong University of Science and Technology’s Tongji Hospital, with all kidney-function indicators reported normal throughout. The engineering challenge these programs share is defeating several distinct rejection mechanisms at once: hyperacute rejection driven by human antibodies against pig cell-surface sugars (targeted by knocking out the GGTA1, CMAH and B4GALNT2 glycan-synthesis genes), acute vascular rejection and clotting incompatibility (addressed by adding human coagulation-regulator genes THBD and PROCR), cellular immune attack (blocked by human complement regulators CD46/CD55/CD59 and tolerance molecules HLA-E/CD47), and the biosafety risk of porcine endogenous retroviruses (PERVs), which CRISPR-Cas9 can now inactivate across all copies in the donor genome.

The key directions of xenotransplantation are:

1. Multiplex glycan knockout: eliminating the pig-specific sugar antigens (alpha-Gal and related glycans) that trigger immediate hyperacute rejection by human antibodies.
2. Human transgene integration: adding human complement-regulator, coagulation-regulator and immune-tolerance genes to the pig genome so the organ is recognized as “self” by the human immune and clotting systems.
3. PERV inactivation: using CRISPR-Cas9 to disable every copy of the porcine endogenous retrovirus in the donor cell genome, eliminating the risk of cross-species viral transmission.
4. Designated pathogen-free (DPF) breeding: raising donor pigs in sealed, monitored barrier facilities to guarantee the organ is free of zoonotic pathogens at the time of transplant.

Sectoral value chain

[CRISPR Design & Genome Engineering] ──> [Nuclear Transfer (SCNT)] ──> [Raising Gene-Edited Pigs]
                │                                     │                              │
       (Vectors, cell lines)                (Embryos, surrogates)          (Sterile DPF conditions)
                                                                                      │
[Human Transplantation] <──── [Organ Procurement & Perfusion] <─────────────────────┘

Value chain levels

Cross-cutting technologies of the sector:

• Multiplex genome editing: introducing dozens of genetic changes into a single cell line simultaneously, requiring high-fidelity Cas nucleases and base editors to avoid chromosomal translocations and off-target mutations.
• Designated pathogen-free (DPF) barrier technology: closed-system pig facilities with positive air pressure, HEPA H14 filtration, effluent decontamination and autoclaved feed, with animals tested monthly against a panel of 30+ swine pathogens.
• Co-stimulation blockade immunosuppression: next-generation monoclonal antibodies (e.g., anti-CD40/anti-CD40L agents such as tegoprubart) that selectively block T- and B-cell co-stimulatory activation pathways, preventing xenograft rejection without fully suppressing the human immune system.

02US

The US is the undisputed global leader in translating xenotransplantation into the clinic, having performed the first-ever successful xenograft surgeries in living patients.

FDA-cleared clinical trials, first-in-human transplants, expanded-access programs

• eGenesis: received FDA IND clearance for EGEN-2784, its genetically engineered porcine kidney, to begin a formal clinical trial for end-stage kidney disease, building on an ongoing expanded-access compassionate-use program with reported patient updates.
• United Therapeutics / Revivicor: its 10-gene-edited UHeart received FDA clearance to proceed with the EXPRESS clinical trial, an adaptive Phase 1/2/3 design for pig-heart xenotransplantation, following the first-ever living-patient pig-heart transplants performed under FDA expanded access.
• Miromatrix Medical (a United Therapeutics company): its miroliverELAP, a bioengineered extracorporeal liver support device built from decellularized porcine liver matrix recellularized with human cells, received FDA RMAT (Regenerative Medicine Advanced Therapy) designation.
• Xenotherapeutics: is running an FDA-regulated clinical trial of porcine skin xenotransplantation for complete wound closure in mixed-depth burns.

03CN

China is rapidly closing the gap with the US, leveraging its massive animal-cloning capacity and advancing non-human primate xenotransplantation studies toward long survival benchmarks.

large-scale pig cloning, primate survival milestones, gene-edited donor platforms

• Zhongke Aoge Biotech (Chengdu): has kept a gene-edited pig kidney functioning in a non-human primate recipient for more than 600 days in collaboration with Huazhong University of Science and Technology’s Tongji Hospital, with all kidney-function indicators reported normal — an internationally leading survival result — built on the company’s integrated gene-edited pig construction and ultra-clean breeding platform.
• Cloning scale: Chinese researchers operate automated robotic micromanipulation systems capable of cloning large numbers of gene-edited pig embryos daily, giving domestic programs a significant throughput advantage.
• Clinical translation pathway: Chinese teams are advancing toward primate-to-clinical-trial pathways for kidney and pancreatic islet-cell xenotransplantation aimed at end-stage renal disease and type 1 diabetes.

04EU

The EU approaches xenotransplantation with characteristic caution, prioritizing deep preclinical primate-compatibility research and strict ethical oversight over rapid clinical translation.

primate preclinical research, ATMP regulatory framework, bioethics oversight

• LMU Munich consortium (Ludwig-Maximilians-Universität, led by Eckhard Wolf): conducts long-term preclinical xenotransplantation research, including deep phenotyping of early human anti-porcine xenograft immune responses and studies defining which genetic modifications of source pigs are essential for successful cell, tissue and organ xenotransplantation.
• EMA regulatory posture: treats xenogeneic organs as Advanced Therapy Medicinal Products (ATMPs), requiring exhaustive preclinical safety evidence with particular emphasis on cross-species infection risk and lifelong clinical monitoring of recipients and their close contacts.
• Ethics oversight: active bioethics committees impose strict constraints on human trials, requiring rigorous justification at every step and minimization of donor-animal suffering.

05Leading companies and research institutes

06Tech stack and innovations

The xenotransplantation industry relies on the following technology stack:

1. Somatic cell nuclear transfer (SCNT):
   • The only method for producing viable cloned pig offspring from deeply edited cell lines: a fibroblast nucleus carrying the edits is microinjected into an enucleated oocyte, electrofused, chemically activated, cultured to blastocyst stage, and implanted in a surrogate sow.
2. Porcine endogenous retrovirus (PERV) inactivation:
   • CRISPR-Cas9 is used to simultaneously cut and disrupt every copy of the PERV pol gene integrated in the donor pig genome, eliminating replication risk and making organs safe for an immunosuppressed human recipient.
3. Normothermic ex vivo organ perfusion:
   • Instead of classic ice storage (which causes ischemic tissue damage), xenografts are connected to a mobile Organ Care System that continuously circulates warm, oxygenated donor blood enriched with nutrients and anti-inflammatory hormones, minimizing vascular injury during transport.

07Value chains and production pipelines

Industrial pipeline of donor pig organ production and preparation for xenotransplantation (GMP/DPF)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. CRISPR editing of pig  │ ───> │ 2. Cloning (SCNT) and     │
│    fibroblasts             │      │    embryo transfer         │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Raising pigs in        │ <─── │ 3. Sterile cesarean       │
│    sterile DPF zones      │      │    delivery                │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Organ procurement in   │ ───> │ 6. Ex vivo perfusion and  │
│    GMP operating room      │      │    delivery to clinic      │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Creating a genetically engineered pig cell line

Primary fibroblasts are isolated from a newborn piglet’s ear and transfected with CRISPR-Cas9 plasmids or ribonucleoprotein complexes targeting the three key pig glycan-synthesis genes (GGTA1, CMAH, B4GALNT2), while human DNA constructs carrying complement genes (CD46, CD55, CD59) and coagulation genes (THBD, PROCR) are introduced by lipofection or electroporation. Clones are selected, whole-genome sequenced to confirm all intended edits with no unwanted DNA breaks, and banked as a master cell line.

Stage 2: Somatic cell nuclear transfer (SCNT)

Oocytes are matured in vitro, enucleated under a micromanipulator, and injected with a single edited fibroblast in the perivitelline space; electrofusion and chemical activation form a reconstructed embryo, which is cultured and surgically transferred to a surrogate sow’s oviduct.

Stage 3: Sterile cesarean delivery

At day 113 of gestation, the surrogate sow undergoes cesarean section under strict sterile conditions in a dedicated DPF operating suite; piglets are immediately transferred to individual sterile incubators, fully preventing transmission of birth-canal pathogens.

Stage 4: Raising pigs in a DPF barrier module

Piglets are raised on sterilized milk replacer and later autoclaved feed and purified water under continuous HEPA-filtered laminar airflow, with staff entering only through a shower airlock; blood and swabs are tested monthly by PCR for porcine cytomegalovirus, lymphotropic herpesvirus and other pathogens until the animal reaches donor-ready size (roughly 80-100 kg at 6-10 months).

Stage 5: Donor organ procurement

The prepared animal is brought to a clean GMP operating room, anesthetized, and the kidney, liver or heart is mobilized; the vasculature is flushed with an ice-cold preservation solution containing human thrombin antagonists before organ removal.

Stage 6: Ex vivo connection, preservation and logistics

The procured organ is weighed, inspected, and connected to a sterile Organ Care System perfusion device circulating modified human red blood cells, electrolytes, hormones and antibiotics at 37°C and 60-80 mmHg perfusion pressure, with continuous pH, lactate and organ blood-flow monitoring during transport (up to 12 hours) to the recipient’s clinic.